Pd 1 and pdl 1 inhibitors market
PD-1 and PD-L1 Inhibitor Market, By Type of Inhibitor (PD-1 Inhibitors, PD-L1 Inhibitors), By Cancer Type (Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
- Mar 2024
- CMI173
- 169 Pages
- Excel & Pdf
- Pharmaceutical
Summary
N/A
Table of Content
Table of Contents:
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Type of Inhibitor
- Market Snapshot, By Cancer Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Rise in incidence/prevalence of cancer
- High cost of cancer treatment
- Rise in research and development activities
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product launch/Approvals
- PEST Analysis
- PORTER’s Analysis
- Merger and Acquisition Scenario
- Market Dynamics
- Global PD-1 and PD-L1 Inhibitor Market – Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- Economic Impact
- Global PD-1 and PD-L1 Inhibitor Market, By Type of Inhibitor, 2019-2031, (US$ Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 – 2031
- Segment Trends
- PD-1 Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
- PD-L1 Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
- Introduction
- Global PD-1 and PD-L1 Inhibitor Market, By Cancer Type, 2019-2031, (US$ Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 – 2031
- Segment Trends
- Kidney
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
- Melanoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
- Bladder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
- Non-small Cell Lung Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
- Liver
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
- Head & Neck
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
- Introduction
- Global PD-1 and PD-L1 Inhibitor Market, By Distribution Channel, 2019-2031, (US$ Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 – 2031
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
- Introduction
- Global PD-1 and PD-L1 Inhibitor Market, By Region, 2019-2031, (US$ Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 – 2031
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Inhibitor, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 – 2031, (US$ Bn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Inhibitor, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 – 2031, (US$ Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Inhibitor, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 – 2031, (US$ Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Inhibitor, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 – 2031, (US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Inhibitor, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 – 2031, (US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Inhibitor, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 – 2031, (US$ Bn)
- North Africa
- Central Africa
- South Africa
- Introduction
- Competitive Landscape
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Gilead Sciences Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- F. Hoffmann-La Roche AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Regeneron Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GSK plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Ono Pharmaceutical Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- BeiGene LTD
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Analyst View
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
- References and Research Methodology
- References
- Research Methodology
- About us and Sales Contact
Segmentation
Market Segmentation
- Type of Inhibitor:
- PD-1 Inhibitors
- PD-L1 Inhibitors
- Cancer Type:
- Kidney
- Melanoma
- Bladder
- Non-small Cell Lung Cancer
- Liver
- Head & neck
- Others
- Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Frequently Asked Questions -
What will be the CAGR of PD-1 and PD-L1 Inhibitor Market?
The CAGR of PD-1 and PD-L1 Inhibitor Market is projected to be 18.3% from 2024 to 2031.
What are the major factors driving the PD-1 and PD-L1 Inhibitor Market growth?
Increase in cancer incidence and growing geriatric population are the major factors driving the growth of PD-1 and PD-L1 Inhibitor Market.
What are the key factors hampering growth of the PD-1 and PD-L1 Inhibitor Market?
High cost of cancer treatment and side effects associated with PD-1 and PD-L1 inhibitors are the major factors hampering the growth of PD-1 and PD-L1 Inhibitor Market.
Which is the leading Type of Inhibitor in the PD-1 and PD-L1 Inhibitor Market?
In terms of Type of Inhibitor, PD-1 Inhibitors is estimated to dominate the market revenue share 2024.
Which are the major players operating in the PD-1 and PD-L1 Inhibitor Market?
Pfizer Inc., Novartis AG, AstraZeneca PLC, Gilead Sciences Inc., Amgen Inc., Sanofi AG, F. Hoffmann-La Roche AG, Merck & Co., Bristol-Myers Squibb Company, Regeneron Pharmaceuticals Inc., Merck & Co., GSK plc, Ono Pharmaceutical Co., Ltd., Eli Lilly and Company, and BeiGene LTD are the major players.
Which region will lead the PD-1 and PD-L1 Inhibitor Market?
North America is expected to lead the PD-1 and PD-L1 Inhibitor Market.